New formulations of iron chelators that target multiple factors involved in AD pathogenesis include M30, a compound that also decreases APP expression and tau phosphorylation, and aroyl nicotinoyl hydrazones (especially SNH6), which also reduce oxidative stress via the elevation of NAD+ levels and the subsequent implementation of sirtuin activity, which results in protection against axonal damage [572,573,574]. Here, APP is linked to Alzheimer disease.